Skip Navigation Links
SEARCH  



 
Bookmark and Share
Senhwa’s Silmitasertib Receives US FDA Orphan Drug Designation for the Treatment of Biliary Tract Cancer
TAIPEI and SAN DIEGO, Jan. 20, 2022 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and...

Full "IntellAsia: Resources" article




Disclaimer | Terms Of Use And Privacy Statement


© Metals News. All rights reserved.